Similarly, combination of IDO/TDO inhibitors and other therapies (chemotherapy, radiotherapy, targeted therapy, and immunotherapy) should be pursued to determine the safety and therapeutic efficacy in LC. Here, IDO1 is linked to laryngotracheoesophageal cleft.